Table 1.
TXNIP expression in cancers of the endocrine glands and genital tracts.
| Tumor type | Upstream or downstream molecular | Significance | TXNIP expression | Samples | References |
|---|---|---|---|---|---|
| Breast cancer | p27 and GLUT 1 | Promote the growth of breast cancer cells in vitro and in vivo | Down | Cell lines, tissue | (13) |
| Breast cancer | miR-373 and HIF1α | miR-373 drives the transformation and metastasis of breast cancer | Down | Cell lines, tissue, animal | (14) |
| Breast cancer | c-Myc | C-myc competes with related transcription factor MondoA and drives glucose metabolism | Down | Cell lines | (15) |
| Thyroid cancer | – | Expression correlates with metastatic properties | Down | Cell lines, animal | (16) |
| PTC | – | The expression of TXNIP in PTC tissues was lower than that in normal thyroid tissues | Down | tissue | (17) |
| Renal cancer | UHRF1 | UHRF1 can recruit HDAC1 to the TXNIP's promoter and mediate the deacetylation of histone H3K9 | Down | Cell lines, tissue | (18) |
| Renal cancer | cRAPGEF5 | cRAPGEF5 targets miR-27a-3p to promote the proliferation and migration of RCC | Down | Cell lines, tissue | (19) |
| Bladder cancer | ERK | Improve disease-specific survival | Down | Cell lines, tissue, animal | (20) |
| Prostate cancer | c-Myc and GLS 1 | C-myc activates glutamine 1 (GLS 1) to accelerate the proliferation | Down | Cell lines, tissue | (21) |
| Prostate cancer | NRF2 | RNF2 binds to TXNIP's promoter to increase apoptosis and inhibit proliferation | Down | Cell lines, tissue, animal | (22) |
| Cervical cancer | MondoA | MondoA overexpression inhibited cell proliferation, migration, and invasion | Down | Cell lines | (23) |
| Endometrial cancer | Vitamin D3 | VitaminD3 can increase the expression of TXNIP to inhibit the proliferation of endometrial cancer cells | Down | Cell lines | (24) |
p27, tumor protein 27; GLUT1, Glucose transporter type 1; HIF1α, hypoxia-inducible factor-1α; UHRF1, ubiquitin-like ringfinger domains 1; cRAPGEF5, CircRNA RAPGEF5; ERK, extracellular regulated protein kinases; GLS 1, Glutaminase 1; RNF2, nuclear factor E2-related factor 2.